C3N-01892
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 77.64271047
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- WNT_BETA_CATENIN_SIGNALING+0.470
- ANGIOGENESIS+0.370
- HEDGEHOG_SIGNALING+0.350
- MTORC1_SIGNALING+0.330
- MYC_TARGETS_V2+0.330
- APICAL_SURFACE+0.310
- HYPOXIA+0.310
- APICAL_JUNCTION+0.250
- MITOTIC_SPINDLE+0.250
Top 10 suppressed
- PROTEIN_SECRETION-0.450
- BILE_ACID_METABOLISM-0.220
- INTERFERON_ALPHA_RESPONSE-0.150
- KRAS_SIGNALING_UP-0.140
- OXIDATIVE_PHOSPHORYLATION-0.110
- SPERMATOGENESIS-0.100
- ADIPOGENESIS-0.090
- PEROXISOME-0.060
- FATTY_ACID_METABOLISM-0.050
- ANDROGEN_RESPONSE-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A6VV-01A-22R-A33J-07 | — | E | 0.842 |
| 2 | MDT-AP-0435 | Med | Medulloblastoma | 0.832 |
| 3 | SRR2771207 | — | — | 0.820 |
| 4 | SRR27320688 | — | — | 0.787 |
| 5 | TCGA-A8-A08X-01A-21R-A00Z-07 | — | C | 0.777 |
| 6 | ULC1427T_S35 | — | cohortSQ2 | 0.753 |
| 7 | BS_QP6MSKRE | Spinal Cord Ependymoma | — | 0.751 |
| 8 | DRR168558 | — | — | 0.750 |
| 9 | TCGA-34-5236-01A-21R-1820-07 | — | cohortSQ1 | 0.746 |
| 10 | 88320 | EPN | Supratentorial EPN | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |